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[57] ABSTRACT 
A codrug composition of at least tWo drug compounds 
covalently linked to one another via a labile bond to form a 
single codrug composition, or ionically linked to one 
another to form a single Workings composition, and methods 
of use of the codrug for the treatment of various medical 
conditions. The codrug may be administered by itself or in 
the form of a bioerodible or nonbioerodible substance. 
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MEANS TO ACHIEVE SUSTAINED RELEASE 
OF SYNERGISTIC DRUGS BY 
CONJUGATION 
This application is a continuation of US. Ser. No. 
08/388,855, ?led Feb. 15, 1995, abandoned, Which is a 
continuation-in-part of US. Ser. No. 08/187,462, ?led Jan. 
28, 1994. 
TECHNICAL FIELD 
The present invention is related to the ?eld of controlled 
pharmaceutical delivery, Especially to codrug compounds. 
BACKGROUND ART 
Aprodrug is a compound formed by chemical modi?ca 
tion of a biologically active compound Which Will liberate 
the active compound in vivo by enZymatic or hydrolytic 
cleavage. The primary purpose of employing a prodrug for 
oral administration is to increase intestinal absorption or site 
speci?c absorption or to reduce local side effects, such as 
gastrointestinal irritation. Prodrugs may also be used to 
increase transdermal absorption, by enhancing permeation 
through topical membranes. 
On this basis, prodrugs are not generally classi?ed as 
sustained release dosage forms. HoWever, the ability to 
bioreversibly modify the physicochemical properties of a 
drug alloWs better intestinal transport properties and hence 
can in?uence the drug blood levels versus time pro?le of the 
pharmaceutical compound. Thus, prodrugs can be used to 
increase the strategies for sustained release and, in a limited 
sense, can be sustaining in their oWn right. 
US. Pat. No. 5,176,907 to Leong et al. discloses biocom 
patible and biodegradable poly(phosphoester-urethanes). 
The patent describes therapeutic agent delivery vehicles 
Which include polymers Which are biodegradable because of 
the hydrolyZable phosphoester or P—(O)—O—C bond. A 
particular aspect of the Leong patent is a therapeutic agent 
that can be .Introduced into the poly-phosphoester urethane 
by covalently binding a radical of this therapeutic agent to 
the phosphorous atom of the polymer. The patent describes 
attaching 5-?uorouracil to polyurethane. The patent dis 
closes that drugs With carboxyl groups can be coupled to the 
phosphorous atom via an ester bond Which is hydrolyZable. 
US. Pat. No. 5,194,581 to Leong et al. discloses biode 
gradable polyphosphoesters. A therapeutic agent is pen 
dently bound to a poly(phosphoester) polymeric matrix. 
When the therapeutic agent is pendently attached, it is 
chemically linked through, for example, ionic or covalent 
bonding. The drug is released When the polymeric agent 
biodegrades. A combination of one or more therapeutic 
agents can be incorporated into the composition of the 
invention. The patent discloses therapeutic agents contain 
ing tWo hydroxyl groups that can be directly incorporated 
into the backbone of the polymers. Other therapeutic agents 
can be derivatiZed for incorporation into the backbone. For 
instance, a drug With tWo amino groups can be reacted With 
the carboxyl group of a hydroxyl carboxylic acid. The 
hydroxyl groups can then be used to form the poly 
(phosphoester). A sustained delivery is effected by the 
hydrolysis of the polymeric prodrug. Although Leong dis 
closes that tWo therapeutic agents may be bound to a 
polymer matrix via covalent bonding, he does not disclose 
or suggest that tWo therapeutic agents can be linked to one 
another by covalent bonding as a prodrug as in the present 
invention. 
US. Pat. No. 5,104,877 to Boger discloses a psoriasis 
treatment. Boger describes a carboxy-protecting group used 
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as a prodrug Where the carboxy-protecting group can be 
readily cleaved in vivo. These carboxy protecting groups are 
indicated to be used in the protection of carboxyl groups in 
penicillin and cephalosporin. 
US. Pat. No. 4,489,065 to Walton et al., discloses chon 
droitin drug complexes. The ’065 patent describes that the 
rate of drug release can be controlled in a variety of Ways, 
such as by encapsulation in a material Which dissolves 
sloWly in the body ?uids, by entrapment in a bolus or matrix 
from Which the drug diffuses sloWly, or by conversion into 
a so called “prodrug”, in Which the drug is bound With 
another substance turning it into a substantially inactive 
compound or complex. The drug is gradually released by 
physiological action When injected into the tissues of the 
patient. The ’065 patent discloses chondroitin or chondroitin 
sulphate covalently or ionically bonded to a drug substance 
of the group consisting of chloramphenicol, methotrexate, 
adriamycin, vinblastine, vincristine, vindesine, 
6-mercaptopurine, 5-?uorouracil, penicillin antibiotics, 
cephalosporin antibiotics, and oxacephalosporin antibiotics, 
to form a prodrug. The patent states that the prodrug 
provides controlled release of the drug in a physiological 
environment. The patent discloses that a variety of func 
tional groups are available in chondroitan for covalently 
bonding (particularly carboxyl, COOH, and hydroxyl, OH) 
and for ionic bonding (sulfate —OSO3—, and carboxylate, 
—COO—) With drugs. Covalent bonding can be by Way of 
ester links, —COOY, or amide links, —CONHY—. When 
chondroitin and the drug substance contain a hydroxyl and 
an amino group, the reaction can proceed through the 
formation of a carbamate bond via activation of the hydroxyl 
to a chloroformate moiety With subsequent linking to the 
amine function. The rate of release of the drug from the 
chondroitin or from the linking substance is dependent on 
the type of bonds chosen for linkage. 
US. Pat. No. 5,130,126 to Koyama et al. discloses a 
polymer-drug conjugate and a method of producing it. 
Polymers Which may be used have an alkyleneoxy group as 
a repeating unit such as polyoxyalkylene glycol as Well as 
polymers obtained by substituting the terminal groups of the 
polymers With an acyl, amino or allyl group. Polymers are 
combined With drugs using covalent bonding, ionic bonding, 
coordinate bonding, and shiff base formation. 
US. Pat. No. 5,057,301 to Wilbur et al. discloses modi?ed 
cellular substrates used as linkers for increased cell retention 
of diagnostic and therapeutic agents. The invention of Wil 
bur et al. comprises a ligand-linker conjugate Wherein the 
linker is a chemically modi?ed cellular substrate having a 
protein conjugation group attached thereto. The protein 
conjugation group attached to the modi?ed substrate linker 
is a functional group Which Will react With the group on the 
targeting protein and form a bond betWeen the linker and the 
protein. Suitable protein conjugation groups include active 
esters (including carboxylic esters, imide esters, succinim 
idyl esters, phenolic esters, and imidate esters), primary or 
secondary amines, hydraZides, hydraZines, carboxylate, 
isothiocyanates, isocyanates, and Michael-type acceptor 
groups such as maleimides, thiols, anhydrides and alkyl 
halides. 
US. Pat. No. 5,171,566 to MiZushima et al. discloses a 
?urbiprofen derivative ophthalmic preparation. The deriva 
tive is an ester of ?urbiprofen. US. Pat. No. 4,933,324 to 
Shashoua is directed to a fatty acid-neuroactive drug con 
jugate used as a prodrug and involves the formation of a 
prodrug from a fatty acid carrier and a neuroactive drug. The 
bond betWeen the fatty acid and the drug may be an amide 
or an ester bond. US. Pat. No. 4,975,278 to Senter et al. 
6,051,576 
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discloses antibody-enZyme conjugates in combination With 
prodrugs for the delivery of cytotoxic agents to tumor cells. 
US. Pat. No. 4,267,326 to OZaki et al. discloses uracil 
derivatives. The uracil derivatives are prepared by reacting 
5-?uorouracil With an ot-haloalkyl carboxylate or an alde 
hyde diacylate. 
US. Pat. No. 4,897,260 to Ross et al. discloses glucocor 
ticoid carboxylic acid esters Which include triamcinolone 
acetonide 21-oic methylester for the treatment of xeroderma 
pigmentosum. 
US. Pat. No. 4,910,192 to Avery et al. discloses topically 
active steroidal anti-in?ammatory agents. The agents are 
12-[3 substituted glucocorticoids Wherein the 12 substituent 
is a hydroxyl group or a lipophilic group attached to a 
12-[3-hydroxyl group. The lipophilic group may be selected 
from an alkyl or aryl substituted ester, an ester, a carbamate 
and a carbonate groups. The 12th substituent can be a loWer 
carboxylic acid ester of a 12-[3-hydroxy group. 
US. Pat. No. 5,177,064 to Bodor discloses targeted drug 
delivery via phosphonate derivatives. US. Pat. No. 5,112, 
835 to Miyasaka et al. discloses 6-substituted acyclopyri 
midine nucleoside derivatives for use as antiviral agents. 
Chemical Abstracts, Volume 117(8), abstract no. 76315(m) 
discloses the stereoselective enZymatic hydrolysis of various 
ester prodrugs of ibuprofen and ?urbiprofen. 
Chemical Abstracts, Volume 116(18), abstract no. 181046 
(b) describes the preparation of prodrugs of ?urbiprofen, its 
1,2-ethanediol ester and 1,4-butanediol ester. The prodrugs 
shoWed high stability in simulated gastric ?uid, simulated 
intestinal ?uid and simulated pancreatic ?uid. The drugs 
shoWed less toxicity and increased anti-in?ammatory and 
analgesic effects. 
None of the above patents disclose or suggest prodrug 
conjugates of tWo or more of the same or different drugs 
linked to one another. Nor do they disclose codrug conju 
gates Which are linked by reversible covalent bonds, such as 
ester, carbamate and carbonate bonds, so that at the desired 
site in the body they are cleaved to regenerate the active 
forms of each of the drugs. 
Patient compliance in consumption of pharmaceutical 
compositions as part of a therapeutic regimen is critical for 
patient recovery and treatment. This is especially critical in 
elderly patients Who may have poor memory and Who 
exhibit poor patient compliance With a therapeutic regimen 
of doses of pharmaceutical compositions. Other high risk 
compliance groups include drug addicts, alcoholics and 
those requiring long term therapy, for example tuberculosis 
patients. 
Furthermore, knoWn erodible, implantable pharmaceuti 
cal substances such as polylactic acid and polyurethane 
compounds are formulated such that it is di?icult to achieve 
high drug loading and hence difficult to deliver large doses 
of drug from the substrate. Such drug substances have loW 
solubility. 
There is a need in the pharmaceutical arts for pharma 
ceutical compounds Which deliver tWo or more drugs at a 
single time in a single dose, Which exhibit controlled drug 
delivery. In one embodiment, the pharmaceutical com 
pounds of the present invention are delivered in a totally 
erodible drug delivery device capable of delivering tWo or 
more synergistic drugs over a prolonged period. The codrug 
compounds of the present invention have the advantage that 
linking the tWo drug compounds decreases the solubility of 
each through the carbamate, carbonate and ester bonds 
linking the compounds. The codrug compounds of the 
invention have a high degree of chemical or enZymatic 
lability at physiological pH 7.4. 
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BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 shoWs a typical release mechanism. Amongst the 
advantages of these systems are that as no polymers are 
required to control release so the devices can be extremely 
small (small enough to be ?tted onto a haptic of an intraocu 
lar lens) (IOLs). 
FIG. 2 shoWs devices Were implanted subconjunctivally 
in each eye of ten rabbits. 
FIG. 3 shoWs codrug devices are entirely composed of 
drug and do not require release rate controlling polymers 
enabling extremely small systems to be prepared. 1.5 mm 
pellets containing 1.5 mg of triamcinolone acetonide (TRI) 
and 0.5 mg 5-?uoroaracil (5FU) Were small enough to be 
?xed to the haptics of IOLs. 
FIG. 4 shoWs bioerodible codrug implants Were prepared 
1.5 mm in diameter and attached to 6-0 nylon suture. 
Implants Were immersed in 5 ml of phosphate buffer (pH 
7.4) and samples periodically removed for HPLC assay to 
determine the release of both 5FU and TRI. Implants Were 
then inserted into the vitreous of 14 NeW Zealand White 
rabbits. 
FIG. 5 shoWs that codrug formulations may be used in the 
treatment of arthritic conditions by injection into the affected 
joint. 
DISCLOSURE OF THE INVENTION 
An object of the invention provides sustained release 
delivery of tWo or more pharmacologically active com 
pounds. The drug compounds may be the same or different. 
Also provided for is a codrug composition, comprising at 
least tWo drug compounds covalently linked to one another 
via a labile bond to form a single codrug composition. 
Also provided for is a codrug composition Wherein drug 
compounds may be linked by labile bonds to another entity 
such as polyethylene glycol, glycerol or a sugar. 
An object of the invention providers a codrug Wherein at 
least one or more of the drug compounds is selected from the 
group consisting of an antiviral compound, a beta-blocker, 
an antibacterial compound, and a biological compound With 
pharmacological activity. 
The invention provides a codrug composition in solid 
form, a codrug composition Which is applied topically for 
examples in a form selected from the group consisting of a 
transdermal patch, ointment, cream, suspension, liquid and 
eyedrop. 
A codrug according to the invention may be administered 
by a method selected from the group consisting of injection, 
inhalation, implantation, applied nasally such as a nasal 
spray, applied rectally, ingested orally and applied vaginally. 
Another embodiment of the invention provides a codrug 
composition attached to a surgically implantable device, for 
example, a codrug attached to a suture. Another embodiment 
of the invention provides a codrug composition is in the 
form of a nonerodible delivery vehicle Which for example 
comprises polyvinyl alcohol. 
The codrug of the invention may comprise from 0.1 to up 
to about 100% of said nonerodible delivery vehicle. 
Another object of the invention is to provide local deliv 
ery of tWo or more synergistic pharmacologic agents or 
delivery of tWo or more non-synergistic pharmacologic 
agents. 
Another object of the invention provides an insoluble 
codrug of TRI linked to 5FU. Another object of the invention 
provides an insoluble codrug of ?urbiprofen (FB) With 5FU. 
6,051,576 
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Another object of the invention provides an insoluble codrug 
of acyclovir (ACV) with EB. Another object of the invention 
is to produce an insoluble codrug of an angiostatic steroid, 
3a,17ot-21-trihydroxy-5[3 pregnane-20-one (THS), With 
5FU. Another object of the invention is to produce an 
insoluble codrug of prostaglandin E2 alpha (PGFZot) With 
timolol (TM). Another object of the invention provides 5FU 
linked to tWo molecules of EB, While another object pro 
vides THS linked to 5FU and PB. 
The totally erodible drug delivery device is capable of 
delivering tWo or more synergistic drugs over a prolonged 
period. 
Another object of the invention is to control the release 
rate of 5FU and triamcinolone from pellets of 5FU/TRI in a 
buffer. 
Still another object of the invention is directed to the use 
of codrugs in the inhibition of posterior capsular opaci?ca 
tion (PCO) after extracapsular cataract extraction and 
intraocular lens implantation. 
A further object of the invention investigates the feasi 
bility of codrug technology as a means to achieve the 
intravitreal delivery of 3a,17ot-21-trihydroxy-5[3 pregnane 
20-one (THS), a model angiogenesis inhibiting steroid, and 
5FU. 
Another object of the invention provides a totally bio 
erodible sustained release system for 5FU and triamcinolone 
in the eye. 
An additional object of the invention provides a codrug 
Which is a salt of amiloride and suramin Which inhibits 
angiogenesis and a method of use of this codrug to inhibit 
angiogenesis. 
DESCRIPTION OF THE INVENTION 
The present invention provides a means of improving the 
pharmaceutical and pharmacological properties of pharma 
cologically active compounds or prodrugs by conjugating 
them together to form a codrug. 
Codrugs are formed by conjugation of tWo or more agents 
via a labile linkage. Codrug conjugates may be linked via 
reversible covalent bonds such as ester, carbonate, cyclic 
phosphate ester and carbamate bonds, so that at the required 
site in the body they are cleaved to regenerate the active 
forms of the drug compounds. Bonds may be, but are not 
limited to the type 
Wherein Z is O, N, CH2, CHZO or CHZS, Y is O, or N, and 
X is O or S. The rate of cleavage of the tWo drugs can be 
controlled by the type of bond, the choice of drugs and the 
physical form of the conjugate. The bond selected may be 
enZyme-speci?c. The bond may be selected from enZymati 
cally labile bonds, for example, to esterases as in the 
ACV-FB linkage, or may be chemically labile (eg. base 
catalyZed hydrolysis of the 5FU-TRI linkage). The codrugs 
are labile in Water, serum or other bodily ?uids and regen 
erate the active parent drugs. The present invention is the 
?rst to combine tWo or more drugs in the form of a codrug 
Which generates tWo active drug compounds With improved 
pharmaceutical properties. 
In an embodiment of the present invention, codrugs have 
the applicability of providing a controlled or sustained 
release for a systemic or local pharmacologic or physiologic 
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effect relating to the folloWing areas: treatment of cancerous 
primary tumors; chronic pain; tuberculosis; arthritis; rheu 
matic conditions; hormonal de?ciencies such as diabetes; 
and modi?cations of the immune response such as in the 
prevention of transplant rejection and in cancer therapy. A 
Wide variety of disease states may be prevented or treated 
using the codrug compositions of the present invention. 
Such disease states are knoWn to those of ordinary skill in 
the art (see Goodman and Gilman, The Pharmacological 
Basis of Therapeutics, 8th Ed., Pergamon Press, NY, 1990; 
and The Merck Index, 11th Ed., Merck and Co., Inc., 
RahWay, N]. 1989; incorporated herein by reference in their 
entireties). 
In addition, codrug compositions of the present invention 
are suitable for treating mammalian organisms infected With 
the AIDS virus, manifestations of AIDS such as Kaposi’s 
sarcoma, and AIDS related opportunistic infections such as 
cytomegalovirus retinitis, toxoplasmosis, Pneumocystis car 
nii and microbacterial avium intracellular. 
A codrug of the invention may consist of one or more 
pharmacologically active compounds in the folloWing 
classes of agents; anesthetics and pain killing agents such as 
lidocaine and related compounds and benZodiaZepain and 
related compounds; anticancer agents such as 5 -?uorouracil, 
adriamycin and related compounds; anti-in?ammatory 
agents such as 6-mannose phosphate; anti-fungal agents 
such as ?uconaZole and related compounds; antiviral com 
pounds such as trisodium phophomonoformate, 
tri?uorothymidine, acyclovir, ganciclovir, dideoxyinosine 
(ddI), dideoxycytidine (ddC); cell transport/mobility imped 
ing agents such as colchicine, vincristine, cytochalsian B 
and related compounds; anti-glaucoma drugs such as car 
bonic anhydrase inhibitors, beta blockers, miotics, cholinest 
erase inhibitors, and sympathomimetics; immunological 
response modi?ers such as muramyl dipeptide and related 
compounds; cytokines and peptides/proteins such as 
cyclosporin, insulin, groWth factor or groWth hormones and 
steroids. Non steroidal anti-in?ammatory agents include, for 
example, ?urbiprofen and indomethacin. 
Codrugs may also be formed of unstable drugs and other 
compounds to improve their stability such as levodopa and 
the peripheral decarboxylase inhibitor benseraZide. 
Codrug formulations may comprise a number of other 
substituents to optimiZe release, bioavailability or appear 
ance and may be used in sustained release devices or 
systems. Such substituents are knoWn to those of ordinary 
skill in the art and for example are set forth in Remington ’s 
Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., 
Easton, Pa., 1990. 
Another embodiment of the p)resent invention comprises 
a codrug compound in a nonerodible matrix or reservoir 
system containing natural or synthetic polymers that are 
biologically compatible With and essentially insoluble in 
body ?uids. Such materials include for example, but are not 
limited to polyvinyl acetate, polyvinyl alcohol, cross-linked 
polyvinyl butyrate, ethylene ethyl acrylate copolymer, poly 
ethyl hexyl acrylate, polyvinyl chloride, polyvinyl acetals, 
plasticiZed ethylene vinyl acetate copolymer, ethylene vinyl 
chloride copolymer, polyvinyl esters, polyvinyl butyrate, 
polyvinyl formal, polyamides, polymethyl-methacrylate, 
polybutyl methacrylate, plasticiZed polyvinyl chloride, plas 
ticiZed nylon, plasticiZed soft nylon, plasticiZed polyethyl 
ene terethphalate, natural rubber, polyisoprene, 
polyisobutylene, polybutadiene, polyethylene, 
polytetra?uoroethylene, polyvinylidine, chloride, 
polyacrylonitrile, cross-linked polyvinyl pyrrolidone, 
polytri?uorochloroethylene, chlorinated polyethylene, poly 
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(1,4,-isopropylidne diphenylene carbonate), vinylidine 
chloride, acrylonitrile copolymer, vinyl chloride-diethyl 
fumarate copolymer, silicone rubbers (especially medical 
grade polydimethylsiloxanes, ethylene-propylene rubber, 
silicone-carbonate copolymers, vinylidine chloride-vinyl 
chloride copolymer, vinyl chloride-acrylonitrile copolymer 
and vinylidine chloride acrylonitrile copolymer. 
In another embodiment, a totally bioerodible sustained 
release system for pharmacologically active agents is com 
posed of codrug alone (either solid, liquid or colloidal). 
Injectable codrug systems have a variety of applications 
including, but not limited to arthritis (FIG. 5). 
The codrug of the invention may be administered in 
injectable form selected from the group consisting of 
liposomes, liquids, suspensions and microsphere nanopar 
ticles. Preparation of such aqueous solutions, liposomes, 
emulsion and suspensions are knoWn to those of ordinary 
skill in the art (see Remington’s Pharmaceutical Sciences, 
18th Ed., Mack Publishing Co., Easton, Pa., 1990, pp. 
1504—1712, incorporated herein by reference). 
Another embodiment of the invention provides a totally 
bioerodible sustained release system for pharmacologically 
active agents composed of codrug in a formulation With 
another bioerodible substance such as polyvinyl acid, 
polyanyhydride, collagen, or polyalkylcyanoacrylates such 
as polybutylcyanoacrylate. 
Examples of codrugs of the present invention include 
5 -?uorouracil With corticosteroids, acyclovir With ?urbipro 
fen and timolol (a beta-blocker) With the prostaglandin 
PGF2-alpha. These codrugs are labile When dissolved in 
bodily ?uids and are rapidly hydrolyZed to regenerate the 
tWo active parent drugs. In the solid form hoWever, they are 
stable, even in an aqueous environment because in order to 
hydrolyZe they must ?rst be in solution. 
Pellets of codrugs of the invention, therefore, sloWly 
release drugs in solution or bodily ?uids re?ecting the loW 
solubility of the conjugated forms. Pellets may be formu 
lated from the codrug compounds alone or With implantable, 
bioerodible substances may be selected from polylactic acid 
and polyclycolic compounds. Pellets may be formulated by 
methods knoWn in the art and may contain 0.1 to about 
100% of the codrug composition. 
Codrugs may also be formulated in bioerodible or non 
bioerodible delivery systems to further control their release. 
Such bioerodible systems include polylactic acid 
(bioerodible) to form a ?lm around, or a matrix With a 
codrug to further improve the pharmaceutical properties. 
Polylactic acid can be formulated in solutions of 2, 5 and 
10% polylactic acid, and has been used to produce 5FU-TRI 
codrug pellets attached to sutures. 2% polyvinyl alcohol has 
been used to coat pellets of 5FU-THS for subconjunctival 
delivery. Polybutyl cyanoacrylate (bioerodible) has been 
used to form a matrix With 5FU-TRI pellets attached to an 
intraocular lens haptic and silicone (nonbioerodible) to 
attach the same pellets to lens haptic (see Example 7 beloW). 
Furthermore, in one embodiment of the invention a phar 
macologically active composition possessing some undesir 
able effects may be conjugated to another agent to reduce the 
undesirable effects such as isoniaZid With pyroxidine. 
Another embodiment of the invention is a codrug formulated 
With other drug or prodrug molecules. 
Amongst the advantages of codrug systems are that 
frequently no polymers are required to control release so that 
the devices can be extremely small (small enough to be ?tted 
onto a haptic of an intraocular lens). Codrugs systems can 
also be formulated as suspensions (nanoparticle siZe range) 
and upper siZe limitations are only imposed the application 
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method under consideration. There are also no concerns of 
residual polymer after drug has been released, nor of poly 
mer related toxicity as no polymers are used in the con 
struction of the devices. 
Some speci?c examples of codrugs of the invention are 
given beloW: 
EXAMPLE 1 
Codrug from triamcinolone acetonide and bis 
(hydroxymethyl)-5-?uorouracil (See scheme 1 beloW) 
Bis(hydroxylmethyl)-5-?uorouracil (2) (158 mg) Was dis 
solved in 5 ml. of acetonitrile in an ice bath. To this stirred 
solution 112 ML of triethylamine Was added folloWed by 
triamcinolone acetonide 21-chloroformate (1) prepared from 
240 mg of triamcinolone acetonide. The resulting solution 
Was stirred at room temperature overnight, concentrated in 
vacuo, redissolved in methylene chloride and Washed With 
Water and brine. The crude product Was chromatographed on 
silicagel using chloroform-methanol=100:5 as a solvent 
system, 210 mg of solid codrug 17 Was obtained. Yield 
61.4%; 1H-NMR (CDCl3); 6 0.95 (s,3H C-18), 1.2 (s,3H 
C-19), 1.4, 1.55 (2s,6H isopropylidene), 3.25 (m, 1H C-16), 
4.4 (m, 1H C-11), 4.8 5.15 (2d, 2H C-21), 5.0 (d, 1H OH), 
5.7—5.85 (2d, 2H CHZN), 6.15 (s,1H C-4), 6.35 (d,1H C-2), 
7.3 (d,1H C-1), 7.65 (d,1H pyrimidyl H-6), 10.0 (s,1H NH). 
EXAMPLE 2 
Hydrolysis of 5FU/T RI 
This example measured the chemical and enZymatic 
hydrolysis of the 5FU/TRI codrug and determined the 
release of drug entities. 
A stock solution Was prepared by dissolving 10 mg of 
5FU/TRI in 10 ml acetonitrile. This Was then added to a 
series of phosphate buffers at pH 3, 5, 6.4, 7.4 and 8.4 at 37° 
C. to give ?nal concentrations of 100 ug/ml. Care Was taken 
to ensure that these solutions Were indeed solutions and not 
suspensions. Samples Were periodically removed and 
assayed by HPLC as described beloW. EnZymatic hydrolysis 
Was determine in a similar Way using pooled serum from 3 
volunteers. The assay procedure used distinguished betWeen 
TRI and 5FU/T RI. 5FU Was assayed under different condi 
tions. 
HPLC Assays 
Samples of buffer containing codrug and hydrolysis prod 
ucts Were assayed by HPLC using a fully automated Hitachi 
system With a C-18 reverse phase column (25 cm><4 mm><5 
pm) and uv detection. The mobile phase Was 40% acetoni 
trile buffered to pH 4.0 With 0.02% sodium acetate. The ?oW 
rate Was 1.0 ml/min and detection Was at 238 nm. Under 
these conditions the retention time of the codrug 5FU/TRI 
Was 17 minutes While triamcinolone acetonide eluted at 9 
minutes. Quantitation limits Were 0.3 and 0.5 ug/ml, respec 
tively. Under the above conditions 5FU Was found to elute 
With the solvent front and so Was assayed separately. For 
5FU an Applied Biosystems HPLC system Was used With a 
C-18 reverse phase column (25 cm><4 mm><5 pm) and 0.02% 
sodium acetate buffer mobile phase (pH 4.0). The ?oW rate 
Was 1.0 ml/min and detection Was by uv at 266 nm. Under 
these condition the retention time Was 6.5 minutes and the 
detection limit 0.2 ug/ml. 
Samples of serum Were deproteinated before assay by 
HPLC. 300 pl serum samples Were added to 300 pl aceto 
nitrile in a microcentrifuge tube. After vortex mixing for 10 
seconds tubes Were centrifuged at 14,000 rpm for 30 min 
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utes. To determine the concentration of codrug and steroid 
the supernatant Was injected directly onto the HPLC 
(sensitivity to 0.6 ug/ml and 1.0 ug/ml, respectively). 
To quantitate 5FU it Was necessary to remove acetonitrile 
before analysis. 300 pl of the supernatant Was dried under 
reduced pressure using a speed vacuum. The dried plug Was 
then rehydrated With 150 pl deioniZed Water before assay by 
HPLC. Interference from serum residues reduced sensitivity 
to 1 ug/ml. 
The codrug Was hydrolyZed in a ?rst-order process to 
quantitatively generate 5FU and triamcinolone acetonide. 
The rate of hydrolysis Was much faster at high pH and Was 
extremely fast in serum (half-life, t1 /2, less than 10 minutes). 
pH t/ 
3.0 204 hr 
5.0 12.7 hr 
6.4 78 min 
7.4 14.1 min 
8.4 9.8 min 
Serum 8.8 min 
This example shoWs that although the 5FU/T RI codrug is 
stable in acidic conditions, it is highly labile under physi 
ological conditions, breaking doWn to regenerate 5FU and 
triamcinolone acetonide. 
EXAMPLE 3 
5FU/T RI as a Sustained Release System In Vitro 
This example measures the release rate of 5FU and 
triamcinolone from pellets of 5FU/T RI in phosphate buffer. 
Pellets (2 mg) of the codrug 5FU/TRI Were prepared in a 
1.5 mm pellet press using a modi?ed Parr Instrument Press. 
Pellets Were then immersed in 5 ml phosphate buffer (pH 
7.4, 37° C.) and 300 pl samples removed each day for 6 
days; these Were immediately replaced With 300 pl of buffer. 
Samples Were assayed by HPLC for 5FU/T RI, triamcino 
lone acetonide and 5FU. After 6 days, buffer Was completely 
replaced, to maintain sink conditions, and sampling contin 
ued. 
No intact codrug Was detected in the receptor medium by 
HPLC (detection limit 0.5 ug/ml). Release of triamcinolone 
acetonide Was found to folloW pseudo Zero order kinetics 
With a mean release rate of 1.4+/—0.3 ug/hr. Release of 5FU 
Was found to be 0.4+/—0.06 ug/hr. 
These rates Were maintained until over 60% of triamci 
nolone acetonide and 5FU had been released. The mean ratio 
of 5FU to triamcinolone acetonide concentration (ug/ml) in 
the receptor solution Was 3.40+/—0.15 at all time points, (i.e., 
equimolar release). 
This example demonstrates that codrug delivery systems 
can be used as sustained release agents hoWever a more 
thorough in vivo evaluation must be performed. 
EXAMPLE 4 
5FU/T RI as a Sustained Release System In Vivo 
This example measures the release rate and vitreous 
concentrations of 5FU and TRI from pellets of 5FU/TRI in 
the rabbit vitreous. 
Pellets (2 mg) of the codrug 5FU/T RI Were prepared 
using a 1.5 mm press. These pellets Were then ?xed onto 6-0 
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nylon suture using intraocular lens grade silicone. Silicone 
covered the base of the pellets providing a platform for 
suture attachment. Alternatively a solution of 2% or 5% 
polylactic acid Was used. Pellets attached by both methods 
Were implanted into the vitreous of 8 NeW Zealand White 
rabbits through a small incision through the sclera. For each 
type of device, tWo animals Were killed after 1, 2, 3, and 4 
Weeks and the vitreous and aqueous obtained from the 
froZen sphere. Before death animals Were examined With a 
slit lamp. This platform did not effect release rate (in vitro). 
Pellets Were then implanted into the vitreous of 8 NeW 
Zealand White rabbits in a similar manner to that described, 
except that sclerotomy sites Were smaller in this case (2.5 
TWo animals Were sacri?ced after 1, 2, 3 and 4 Weeks 
and vitreous and aqueous obtained from the froZen sphere. 
HPLC analysis Was then performed on tissue samples and 
explanted devices to determine the concentrations of 5FU, 
triamcinolone acetonide and intact 5FU/T RI. 
No intact codrug Was detected in the vitreous. Mean 
intravitreal levels of triamcinolone Were found to be 3.0+/— 
0.9 ug/ml. These levels Were maintained for three Weeks, 
declining to 0.8+/—0.4 ug/ml on the fourth Week before 
dropping beloW the detection limit of the HPLC by Week 5. 
This experiment shoWs that sustained levels of TRI and 
5FU in the vitreous are achievable by the implantation of a 
codrug device. Such a device has the advantages of being 
composed entirely of the required drugs and of being 
completely bioerodible. No toxic or in?ammatory effects are 
anticipated as the only compounds being released are 5FU, 
triamcinolone acetonide and formaldehyde. 
EXAMPLE 5 
5FU-TRI Codrug Implant to Control Scar 
Formation in Strabismus Surgery 
An in vivo evaluation of scar reduction under 5FU-TRI 
implant after extraocular muscle (EOM) surgery in rabbits, 
an experimental animal model for correlation to human 
utility. 
In each eye of ten rabbits the inferior rectus muscle (IRM) 
Was disinserted from the globe and electrocautery Was used 
to create a scar betWeen the muscle and sclera. After the IRM 
Was seWn back into its insertion site, four 2 mg codrug 
implants Were inserted betWeen sclera and muscle in the 
right eye, While the left Was used as a control. Bioerodible 
codrug implants releasing 5FU and TRI over 6 Weeks Were 
prepared. Devices release equimolar amounts of 5FU and 
TRI. Animals Were killed at 1, 2 and 3 Weeks and eyes 
eviscerated. Specimens Were prepared and stained With 
H&E. The scar thickness and cellular in?ltrate Were deter 
mined quantitatively using a Bioscan image analysis pro 
gram. 
Drug treated eyes shoWed an 80% decrease in scar 
thickness compared to controls (7 to 35 pm). Microscopic 
examination of a de?ned area of tissue (40 pmz) revealed a 
greater number of in?ammatory cells present in the control 
tissue (>300 versus <35). The codrug implant may prove 
useful in scar reduction folloWing EOM surgery. 
EXAMPLE 6 
Bioerodible Sustained Release Subconjunctival Co 
Delivery of TRI and 5FU 
This example determined feasibility of a codrug release 
system for the subconjunctival co-delivery of 5FU and TRI 
for possible use in glaucoma ?ltration surgery. 
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Codrug devices Were prepared as ?at discs 2.5 mm in 
diameter Weighing 5 mg. Each device contained approxi 
mately 3.7 mg of TRI and 1.3 mg of 5FU and Were 
composed of over 97% active substance. Devices Were 
implanted subconjunctivally in each eye of ten rabbits (FIG. 
2). Toxicity and in?ammation Were determined by Weekly 
slit lamp examinations and electroretinograms (ERGs). Ani 
mals Were killed after 3, 7, 10 and 14 days and eyes 
eviscerated. After freezing at —70° C. devices Were removed 
for determination of residual drugs and the complete vitre 
ous and aqueous dissected from the ice ball to determine the 
concentration of 5FU and TRI. TWo animals Were used for 
histology and Were killed 6 Weeks after implantation. 
Analysis of explanted devices shoWed 5FU and TRI to 
have been released at a pseudo Zero order rate of 9 +/—1% 
per day over the ?rst ten days. Devices released equimolar 
amounts of 5FU and TRI. ERGs Were normal for all animals 
and there Was no evidence of toxicity or in?ammation 
around the implantation site. 
EXAMPLE 7 
Codrugs in the Prevention of Posterior Capsular 
Opaci?cation 
This example investigates the use of codrugs in the 
inhibition of posterior capsular opaci?cation (PCO) after 
extracapsular cataract extraction and intraocular lens 
implantation in the rabbit. 
Codrug pellets Were prepared that gave pseudo Zero order 
release of 5FU and TRI in an equimolar ratio over 6 Weeks. 
Codrug devices are entirely composed of drug and do not 
require release rate controlling polymers enabling extremely 
small systems to be prepared. 1.5 mm pellets containing 1.5 
mg of TRI and 0.5 mg 5FU Were prepared and ?xed to the 
haptics of IOLs using the bioerodible polybutyl cyanoacry 
late. This polymer is soaked into the pellet forming a 
codrug/cyanoacrylate matrix as it dried (FIG. 3). 16 NeW 
Zealand White rabbits Were used in this study, one eye 
(control) received a polymethyl methacrylate intraocular 
lens (IOL) (Chiron Intraoptics) While the other received an 
IOL With codrug. Eyes Were examined regularly by slit lamp 
and PCO scored from 0 to 4+. Retinal function Was deter 
mined by electroretinogram (ERG) before implantation and 
before sacri?ce. Animals Were killed after 4, 8, 12 and 16 
Weeks; eyes Were removed and ?xed in formalin. Photo 
graphs of posterior capsule Were projected onto a grid and 
the percentage of PCO calculated. 
ERG and histopathologic data indicated that the codrugs 
Were Well tolerated With no indication of a toxic or in?am 
matory response. Slit lamp examination shoWed a statisti 
cally signi?cant decrease in PCO betWeen study and control 
eyes (p<0.001). The less subjective assessment of PCO 
using a grid con?rmed this observation and indicated an 
arrest of opaci?cation in drug eyes With a statistical signi? 
cance of p<0.03 by 8 Weeks. 
This example indicates that codrug implants are Well 
tolerated in the capsular bag. Signi?cantly, the development 
of PCO can be controlled over a prolonged period by the use 
of these implants. 
EXAMPLE 8 
Intravitreal Co-Delivery of TRI and 5FU 
This example evaluates intravitreal co-delivery of 5FU 
and TRI in an animal model of proliferative vitreoretinopa 
thy (PVR). Previous studies indicate that TRI and 5FU is 
useful in the treatment of PVR. 
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Bioerodible codrug implants Were prepared 1.5 mm in 
diameter and attached to 6-0 nylon suture. Implants Were 
immersed in 5 ml of phosphate buffer (pH 7.4) and samples 
periodically removed for HPLC assay to determine the 
release of both 5FU and TRI. Similar implants Were then 
inserted into the vitreous of 14 NeW Zealand White rabbits 
(FIG. 4). Toxicity Was assessed by electroretinogram and slit 
lamp examination in all animals. Histopathologic examina 
tion Was performed on four animals. Ten animals Were used 
for pharmacokinetics; tWo animals Were killed 1, 2, 3, 4 and 
5 Weeks after implantation. Eyes Were enucleated, devices 
removed and both vitreous and aqueous obtained. All 
samples Were assayed by HPLC. Five animals received 
actual devices in one eye and placebo implants in contralat 
eral eyes. These Were killed after 3 and 6 Weeks for 
histopathologic examination. 
Devices released TRI at 1.4 ug/hr and 5FU at 0.3 pig/hr in 
buffer (equimolar release) and Were Well tolerated in rabbit 
eyes With no indication of toxicity or in?ammation. Vitreous 
levels of TRI Were maintained at 2.4 pig/ml over the 5 Weeks 
duration of the pharmacokinetic study. 
The delivery system described gives pseudo Zero order 
release of both TRI and 5FU in buffer. As the devices are 
small, they can be readily inserted into a normal scleral 
MVR blade incision. The devices appear to be Well tolerated 
and maintain high, potentially therapeutic, drug levels in the 
vitreous. Levels of TRI and 5FU in the aqueous Were too loW 
to be detected. Future Work Will evaluate the use of this 
codrug system in a PVR model. 
EXAMPLE 9 
Intravitreal Delivery of an Anti-Neovascular Agent 
and an Antiproliferative Agent in the Rabbit Eye 
The example shoWs codrug technology as a means to 
achieve the intravitreal delivery of 30., 17a, 21-trihydroxy 
5B pregnane-20-one (THS), a model angiogenesis inhibiting 
steroid, and 5FU. THS has no corticosteroid activity but 
inhibits neovaculariZation in the chick embryo and rabbit 
cornea models. Activity of this and related agents can be 
enhanced by a variety of agents including aurin tricarboxylic 
acid, and cyclodextran. 
Other Workers have reported that antimetabolites can also 
inhibit neovasculariZation. Increased efficacy of THS may 
be anticipated from the coadministration of 5FU. The inven 
tors have developed a bioerodible implantable device by 
preparing a 5FU/THS codrug. In vitro, devices release 2 
moles of 5FU for each mole of THS. 
2 mg codrug devices Were implanted into the vitreous of 
20 NeW Zealand White rabbit eyes (ten animals) through 2.5 
mm incisions parallel to and 3 mm from the limbus. Animals 
Were also examined by slit lamp and retinal function Was 
assessed by electroretinogram (ERG) examination before 
implantation and immediately before sacri?ce. Animals 
Were periodically killed after implantation and eyes imme 
diately enucleated and froZen. Vitreous Was then assayed for 
5FU, THS and intact codrug by HPLC. Explanted devices 
Were also assayed for residual drug. 
Proliferative Vitreoretinopathy 
To treat proliferative disorders in the vitreous or lens 
capsule such as proliferative vitreoretinopathy or posterior 
capsular opaci?cation therapeutic concentrations of 5FU 
(over 0.5 ug/ml) and corticosteroid (1 ug/ml) should be 
maintained so as to at the same time inhibit ?broblast 
proliferation (5FU inhibits groWth of ?broblasts) and pre 
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vent in?ammation Which stimulates their proliferation (TRI 
has potent anti-in?ammatory properties). 
Method to achieve sustained release of tWo or more 
Pharmacologically active compounds or codrugs from an 
injectable formulation. 
A 10 mg/ml suspension of 5FU-TRI codrug Was prepared 
in isotonic phosphate buffer. This Was injected into the 
vitreous of 3 rabbits. One animal Was killed after 1, 3 and 7 
days and both eyes Were removed. HPLC analysis Was 
performed on each eye to detect intact codrug, TRI and 5FU. 
Injection of the suspension Was found to maintain therapeu 
tic levels of both 5FU and TRI in the vitreous over the 7 day 
duration of this study. 
EXAMPLE 10 
A 5FU/TRI codrug conjugate according to the invention 
Was found to be unstable in buffer at pH 7.4, although it Was 
stable in pH 3.0 (respective t1 /2 less than 15 minutes and 
over 5 days). 
The compound is moreover relatively insoluble so that a 
pellet can be compressed that does not dissolve in buffer at 
pH 7.4. Such a pellet sloWly releases both TRI and 5FU over 
an eXtended period of time (months) even When immersed in 
pH 7.4. The advantage of such a system is that although each 
of the parent compounds are released, the intact conjugate is 
never detected in solution (its half-life is too short). This 
conjugate can be formulated into a totally bio-erodible 
sustained release system for 5FU and triamcinolone in the 
eye. Both agents are presently used in combination and a 
sustained release form for one or the other has been a goal 
of ophthalmologists for a long period. 
In a similar Way a conjugate of 5FU and TRI can be used 
as a codrug compound for the treatment of proliferative 
vitreoretinopathy (PVR). A pellet of such an implant With 
similar properties to the above is implanted intravitreally 
after vitrectomy and is found to reduce the occurrence of 
PVR. Animal studies are proceeding. 
An additional manifestation of the codrug idea is the 
conjugation of an anti-viral compound (ganciclovir or 
acyclovir) With a nonsteroidal anti-in?ammatory agent 
(?urbiprofen or indomethacin). These conjugates are 
insoluble and Would be suitable for subconjunctival implan 
tation in herpes keratitis. 
EXAMPLE 11 
The folloWing is the structure of 5FU linked via a car 
bonate bond to a glycerol di?urbiprofen ester. The rationale 
is that the compound Would hydrolyZe in vivo to release 
5FU, glycerol and tWo molecules of ?urbiprofen. 
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EXAMPLE 12 
Codrug from Flurbiprofen and Acyclovir (See 
Scheme 2 BeloW) 
200 mg of acyclovir, 160 mg of ?urbiprofen, 200 mg of 
dicycloheXylcarbodiimide (DCC) and 13 mg of dimethy 
laminopyridine (DMAP) Were miXed With 7 ml of dimeth 
ylformamide. The miXture Was stirred at 55° C. overnight, 
then evaporated to dryness under vacuum. The solid residue 
Was chromatographed on silicagel to yield 340 mg of the 
codrug (3a). 1H-NMR (DMSO), 6 1.4 (d, 2H CHZO), 3.8 (q, 
1H CH), 4.1 (m, 2H), 5.3 (s,2H NCHZO), 6.5 (s, 2H NHZ), 
7.15—7.55 (m,8H arom.), 7.8 (s, 1H CH). 
EXAMPLE 13 
Codrugs from bis(hydroXymethyl)-5-?uorouracil and ?ur 
biprofen (See scheme 3 beloW) 
Flurbiprofen acid chloride (282 mg) Was dissolved in 3 ml 
of acetonitrile. To this stirred solution triethylamine (142 
mg) Was added folloWed by 5-?uorouracil (2) derivative 
(170 mg). The cloudy miXture Was stirred at room tempera 
ture overnight, diluted With dichloromethane, then Washed 
With aqueous NaHCO3 solution, Water and brine. Chroma 
tography on silica gel yielded 2 codrugs (4a). 145 mg of 
monosubstituted product and 160 mg of bissubstituted prod 
uct. 1H-NMR (acetone) for monoester, 6 1.7 (d,3H CH3), 3.9 
(q, 1H CH), 5.75 (s,2H CHZN), 7.2—7.6 (m,8H arom.), 7.92 
(d,1H). 1H-NMR (acetone) for diester, 6 1.5 (m, 6H 2CH3), 
3.75 (m, 2H 2CH), 5.6 (s,2H CHZN), 6.0 (s, 2H CHZN), 
7.0—7.6 (m,16H arom.). 
EXAMPLE 14 
Codrug from Prostaglandin PGFZOL and Timolol 
102 mg of protected prostaglandin PGFZOL Was dissolved 
in 4.5 ml of methylene chloride at 0° C. To this solution 
carbonyldiimidaZole (35 mg) Was added and the resulting 
solution Was stirred at 0° C. for 40 min. The solution of 
timolol (54 mg) in 1 ml of methylene chloride Was then 
added and the mixture Was heated at 50—54° C. overnight. 
The solution Was Washed With Water and brine. Thus 
obtained crude product Was puri?ed by chromatography and 
redissolved in tetrahydrofuran (3 ml) at 0° C. To this stirred 
solution tetrabutylammonium ?uoride Was added. After 0.5 
h the solvent Was evaporated, the residue Was dissolved in 
ethyl acetate, Washed With dil. sodium bicarbonate solution, 
brine and dried over Na2SO4. The oily residue Was puri?ed 
by preparative TLC to yield the eXpected codrug (39% of 
yield). 1H-NMR (CDCl3), 6 0.85 (t, 3F CH3), 1.1 (s, 9H 
t-Bu), 2.56 (d,2H CHZN), 3.5 (m,4H), 3.8 (m,4H), 3.9—4.2 
(m,4H 3CHO+OH), 4.6 (m, 2H CHZO), 5.25 (m, 1H 
CH—O), 5.3—5.6 (m, 4H ole?ne). 
Synthesis Scheme 
COOH 
1. TMS-Cl 
2. timolol, DCC 
DMAP 
OH 
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EXAMPLE 15 
Codrug made of 5[3-pregnane-3ot, 170., 21-triol-20 
one, ?urbiprofen and 5-?uorouracil (scheme 4) 
1.4 ml of the solution of phosgene in toluene and 1 ml of 
the THF Were cooled to 0° C. in an ice-bath. To this stirred 
mixture the solution of (5) (60 mg) and triethylamine (14.5 
ML) in 1.5 ml of THF Was sloWly added. After 6 h the excess 
of phosgene and the solvent Were removed in a stream of 
nitrogen. The residue Was diluted With 1 ml of acetonitrile 
and the solution of bis(hydroxymethyl) -5-?uorouracil (2) 
(50 mg) and triethylamine (29 pL) in 1.5 ml of acetonitrile 
Was added. The resulting homogenous solution Was kept in 
refrigerator overnight. The residue obtained after solvent 
evaporation Was puri?ed by preparative TLC yielding 52 mg 
of the codrug 1H-NMR (CDCl3), 6 0.6 (s, 3H C-18), 0.9 
(s,3H C19), 1.52 (d,3H CH3), 3.7 (q,1H CH), 4.75 (m,1H 
C-3), 4.8—5.3 (2d,2H C-21), 5.7 (s,2H CHZN), 7.1—7.55 
(m,8H arom.), 7.6 (d, 1H CH). 
EXAMPLE 16 
Esters of acyclovir With ?urbiprofen and indomethacin 
have been synthesized as shoWn in Scheme 2 set forth 
beloW, from the corresponding acids (activated With N,N 
dicyclohexylcarbodiimide). Using this method the ester of 
?urbiprofen 3a has been readily obtained, but When 
indomethacin Was used the amidoester 3b surprisingly Was 
isolated from the reaction mixture. 
The conjugate of ganciclovir and indomethacin has been 
synthesiZed as presented in Scheme 5. This diester could not 
be obtained by simple esteri?cation. HoWever, When the 
primary amino group Was protected as an N-trityl derivative 
7 (via the intermediate diactetate), the acylation With excess 
of indomethacin acid chloride gave the expected diester 8. 
Synthesis of the monoester of ganciclovir With 
?urbiprofen, Scheme 6, required selective protection of one 
of the tWo primary hydroxyl groups in ganciclovir 9. This 
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Was achieved by treating the latter With 2.5 eq. of 
monomethoxytrityl chloride in the presence of triethylamine 
and DMAP. The resulting ditrityl derivative 10 Was treated 
With ?urbiprofen acid chloride to give the fully protected 
monoester 11. Removal of the trityl groups With acetic acid 
provided the desired codrug 12. 
EXAMPLE 17 
Conjugates of 5-?uorouracil With ?urbiprofen, 
indomethacin, and triamcinolone acetonide. 
5FU remains a clinically important antiviral and antitu 
mor agent, but it possesses high toxicity and far from 
optimal delivery properties. Synthesis of a series of 5FU 
conjugates With anti-in?ammatory drugs such as 
?urbiprofen, indomethacin, and triamcinolone acetonide 
resulted in compositions With improved properties. 
5FU can be attached to hydroxy compounds as carbamate 
(via the intermediate chloroformate) as shoWn in Scheme 7 
beloW. 
In the case of menthol 13, the stable product has been 
obtained. If, hoWever, an oxygen atom is introduced at the 
proximity of the hydroxyl group, the carbamate bond 
becomes very labile. Via NMR, the inventors Were able to 
prove a carbamate bond Was formed. An attempt to prepare 
the carbamate from 5FU and triamcinolone acetonide-21 
chloroformate 1 failed completely. The inventors investi 
gated the esteri?cation of the knoWn 1,3-bis 
(hydroxymethyl)-5FU 2 With acid chlorides and 
chloroformate. Compound 2 has been obtained from 5FU 
and formalin as a viscous oil containing ca. 60% of the 
bis-(hydroxymethyl) derivative and ca. 35% of both the 
isomeric mono-(hydroxymethyl) products. This mixture Was 
used in all subsequent reactions Without further puri?cation. 
Flurbiprofen and indomethacin acid chlorides Were 
coupled With 2 in acetonitrile in the presence of triethy 
lamine to give a mixture of the mono and diesters (Scheme 
3). 
In both cases the major product Was the 1-substituted 
derivative and the separation of the mixture did not present 
any dif?culty. 
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An alternative approach involved the use of hydroxyesters 
of ?urbiprofen to attach the 1,3-bis-(hydroxymethyl)-5FU 
via a carbonate link (Schemes 8 and 9). 
In the scheme 8 example, the monoester of ?urbiprofen 
and triethylene glycol 13 Was prepared. the synthesis 
required selective protection of one of the tWo hydroxyl 
groups as a silyl derivative. Subsequent acylation and depro 
tection led to the expected monoalcohol. This product Was 
chloroformylated in THF With a solution of phosgene, and 
coupled With 2 to yield the desired codrug 14. 
Alternatively, ?urbiprofen 1,3-diglyceride 15 Was 
obtained by the methods of Scheme 9. In the ?rst approach, 
dihydroxyacetone Was readily acylated With ?urbiprofen 
acid chloride in the presence of pyridine, and the central keto 
group Was rapidly reduced by sodium borohydride in THF 
solution. Apuri?cation procedure using column chromatog 
raphy on silica gel led to the expected monoalcohol 14. 
The second approach involved the preparation of 1,3 
benZylidene glycerol, protection of the remaining hydroxyl 
group as an O-benZyl derivative, acidic hydrolysis of the 
acetal and acylation of the diol With ?urbiprofen acid 
chloride. Finally the benZyl group Was removed by transfer 
hydrogenation in the presence of 10% Pd/C. Compound 15 
Was chloroformylated and coupled With the 5-?uorouracil 
derivative as described above, to yield the desired codrug 
16. 
Triamcinolone acetonide Was bonded to the 1,3,-bis 
(hydroxymethyl)-5FU 2 via a carbonate (Scheme 1) linkage. 
The product, obtained after the treatment of TRI With 
phosgene, contained only one chlorformyl group. Steric 
considerations make it practically impossible for the reac 
tion to occur With the 11[3-hydroxyl group. The monochlo 
roformate obtained above Was coupled With 2 to give the 
expected crystalline codrug 17 after chromatographic puri 
?cation. 
EXAMPLE 18 
Codrugs Based on 5[3-Pregnane-3ot,17ot,21-Triol 
20-One. 
Triple codrugs composed of 3 components including an 
antimetabolite agent (5FU), and anti-in?ammatory agent 
(?urbiprofen) and an antivasculating agent (5[3-pregnane 
3ot,17(x,21-triol-20-one). 
Initially, tWo model compounds 19 and 20 (Schemes 10 
and 11) Were synthesiZed and evaluated With respect to the 
stability in aqueous solution as a function of pH. 
The easily available 5[3-androgen-3ot-ol-17-one (18) Was 
acylated With ?urbiprofen acid chloride in pyridine in the 
presence of DMAP. The resulting ketoester 19 Was then 
reduced in high yield to the alcohol 20. For the completion 
of the synthesis, the alcohol Was chloroformylated in the 
usual fashion, and coupled With 5FU to yield the expected 
product 21. 
In the second synthesis model, the simple ester 22 of 
?urbiprofen and 5[3-pregnane-3ot,17ot,21-triol-3,20-dione 
Was obtained as shoWn in Scheme 11. Synthesis of all 
“triple” codrugs have been based on the easily available and 
relatively cheap Reichstein’s Substance 23 (Scheme 4). This 
material Was transformed in the usual Way (formalin and 
concentrated HCl in methylene chloride) to its bismethyl 
enedioxy derivative, Which Was then hydrogenated in high 
yield With palladium-on-calcium carbonate in the presence 
of potassium hydroxide, to the saturated 5[3-pregnanone. 
This ketone Was then reduced With sodium borohydride, 
predominantly to the equatorial alcohol 24; the axial alcohol 
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Was obtained as a minor side product. The acylation of 24 
With ?urbiprofen acid chloride yielded the ester 25. For the 
completion of the synthesis, the dihydroxyacetone side 
chain Was liberated by treatment of 25 With hydro?uoric 
acid in THF, and the resulting diol 5 Was chloroformylated 
and coupled With 2 to give the desired codrug 6. 
The synthesis of the next series of codrugs is shoWn in 
Scheme 12. The hydroxyl group of the alcohol 24 Was 
protected as an O-benZyl derivative and then the bismeth 
ylenedioxy group Was hydrolyZed in the usual fashion. The 
selective acylation of the 21-hydroxy group led to the 
?urbiprofen ester 26. The benZyl group Was removed by 
transfer hydrogenation and the resulting alcohol Was con 
verted to the chloroformate 27. This product Was then 
subject to coupling With either 1,3-bis-(hydroxymethyl) 
5FU, 2, or 5FU itself, Which gave the corresponding codrugs 
28 and 29, respectively. Independently the tWo codrugs 
containing only 5FU and 5[3-pregnane-3ot,17ot,21-triol-20 
one Were prepared (Scheme 13). 
The alcohol 24 Was hydrolyZed an(d chloroformylated to 
the bis-chloroformate 30. When compound 30 Was coupled 
With a 3 equivalents excess of 2, the expected codrug 31, 
containing tWo 5FU residues, Was obtained. HoWever, if 
only a 1.5 equivalents excess of 2 Was used, the monocar 
bonate 32 Was isolated. The structure of 32 Was proven by 
1H and 13C NMR analysis. 
Due to the remarkable stability of ?urbiprofen esters at 
pH 7.4, an alternative type of linear unit betWeen ?urbipro 
fen and the steroidal alcohols Was considered (Scheme 14). 
In the reaction of chloroformate 33 With the salt of 
?urbiprofen, it Was expected that a mixed anhydride of 
?urbiprofen and carbonic acid Would be obtained. Instead, 
hoWever, the ester 34 Was isolated as the only product. 
Obviously, 34 is formed from the unstable, intermediate 
mixed anhydride by elimination of carbon dioxide. 
EXAMPLE 19 
Derivatives of AcetaZolamide 
AcetaZolamide is a useful drug for the treatment of 
glaucoma. HoWever, due to its unfavorable lipophilicity it is 
not active When given topically to the eye. Approaches to 
solve the delivery problems may include the development of 
appropriate codrug forms. Preparation of sulfocarbamate 
derivatives of acetaZolamide are shoWn in Scheme 15. The 
product 35 appears to stable in buffer solution to ensure a 
sufficient rate and extent of codrug conversion to the parent 
drug at this time. 
EXAMPLE 20 
The folloWing example relates to a method for making 
and using a suramin and amiloride codrug as a means to 
inhibit angiogenesis. It is Well settled that individually both 
suramin and amiloride are potential therapies for angiogen 
esis and cancer. 
Speci?cally, Vassalli and Belin, FEBS Letters, 
“Amiloride Selectively Inhibits the Urokinase-type Plasmi 
nogen Activator” Volume 214, Number 1, p. 187—191 (April 
1987), describe the selective inhibition of urokinase-type 
plasminogen activator by amiloride in cell culture. Kellen et 
al., “Antimetastatic Effect of Amiloride in an Animal 
Tumour Model”, Anticancer Res., Volume 8, p. 1373—1376 
(1988) shoW that amiloride exerts an anti-metastatic effect in 
a rat model. The anti-angiogenic effects of amiloride have 
been demonstrated in the embryonic egg model (CAM 
assay) by Chen et al., Investigative Ophthalmology and 
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Visual Science, Vol. 35, No. 4, Abstract 1157-28, Mar. 15, 
1994. The same authors have presented data showing a 
bene?cial effect of systemically administered amiloride on 
subretinal neovasculariZation in man (Chen et al., Investi 
gative Ophthalmology and Visual Science, Vol. 35, No. 4, 
Abstract 1171-42, Mar. 15, 1994). 
Suramin, Which inhibits various groWth factors, has been 
shoWn to retard Wound healing When applied in a liposomal 
form (Butler et al., Investigative Ophthalmology and Visual 
Science, Vol. 35, No. 4, Abstract 829-86, Mar. 15, 1994). 
Collins et al., “Inhibition of Angiogenesis by Suramin”, 
Cancer Research, Volume 52, p. 5073—5075 (Sep. 15, 1992) 
and Hassan et al., Investigative Ophthalmology and Visual 
Science, Vol. 35, No. 4, Abstract 566-14, Mar. 15, 1994), 
have also shoWn suramin to be a potent inhibitor of angio 
genesis in the Chick Chorioallantoic Membrane (CAM) 
assay. See also Abstracts 417, Amiloride; and 8696, Suramin 
Merck Index, 11th Ed., Merck and Co., Inc. (1989) and 
references cited therein, incorporated by reference herein in 
its entirety. 
The chemical structures of amiloride and suramin are set 
forth beloW. 
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amount to inhibit angiogenesis of a codrug of suramin 
ionically linked to amiloride to a patient in need of angio 
genesis inhibition. 
Effective dosages of suramin-amiloride codrug are in the 
5 range of about 1—30 mg/kg body Weight and preferably from 
about 10—20 mg/kg body Weight.. The suramin/amiloride 
codrug is preferably formulated into a sustained release 
pellet comprising about 1/2 gram of codrug. The suramin/ 
amiloride codrug may be formulated for ophthalmic use to 
achieve an effective concentration in the eye of 5 mcg/ml of 
codrug components, in a liquid formulation. In the 
alternative, the codrug may be administered intra-arterially 
for the treatment of Kaposi’s sarcoma. The suramin/ 
amiloride codrug may be administered by injection for the 
15 treatment of arthritis. 
EXAMPLE 21 
Codrug from Ethacrynic Acid and Atenolol 
Ethacrynic acid is a diuretic and atenolol is an antihyper 
tensive drug. They may be formulated into a codrug as 
folloWs. 200 mg of ethacrynic acid Was dissolved in 4 mL of 
(II 1TH 
c1 N c c 
I \ NH NHZ 
/ 
HZN N NHZ 
Amiloride 
NaO3S HNOC CONH SO3Na 
503“ CH3 (ED/M1035 
NH NH 
NaO3S SO3Na 
CO CO 
% NHCONH % 
Suramin Sodium 
These reports shoW that although both suramin and 
amiloride individually inhibit angiogenesis, their mode of 
action is different. Thus, the tWo agents administered linked 
together by ionic bonding as a codrug appear to have a 
synergistic effect. 
Amiloride is available from Sigma Chemical Co., St. 
Louis Mo. and Suramin is available from Mobay Chemical 
Co, NeW York, NY. The tWo drugs are ionically linked to 
one another via an ionic bond to form a single codrug salt 
compound. 
The tWo drugs may be ionically linked by mixing solu 
tions of the tWo compounds. Amiloride is dissolved in Water 
to form a saturated solution. Suramin is added to the 
amiloride solution and suramin/amiloride salt forms. Six 
amiloride molecules ionically bond to each single suramin 
molecule. The precipitate is collected. 
A method of inhibiting angiogenesis according to the 
present invention comprises administering an effective 
50 anhydrous dichloromethane and to this stirred solution at 
room temperature 128 mg of DCC Was added folloWed by 
10 mg of dimethylaminopyridine (DMAP) and 128 mg of 
atenolol. The resulting mixture Was stirred at room tempera 
ture overnight, diluted With 30 mL of dichloromethane, 
Washed With sodium bicarbonate solution, Water and brine. 
The residue after solvent evaporation Was chromatographed 
on silicagel to yield 62 mg of the expected codrug. 1H-NMR 
(CDCl3) 6 1.14 (t, 3H), 1.26 (d, 3H), 1.31 (d, 3H), 2.46 (q, 
2H), 3.50 (s, 2H), 3.52 (m, 1H), 4.25 (m, 1H), 4.91 (2d, 2H), 
5.60 (s, 1H), 5.94 (s, 1H), 7.12—7.28 (m, 6H). See synthesis 
sheme 16 beloW. 
60 
EXAMPLE 22 
Codrug from THS, 5-FU and Diethylene Glycol 
3ot,17ot-21-trihydroxy-5[3 pregnane-20-one (THS) can be 
formulated in to a codrug With 5FU and diethylene glycol to 
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form an angiostatic steroid. A biscarbonate of THS and 
diethylene glycol (75.3 mg) Was chloroformylated With 
phosgene in tetrahydrofuran in the presence of triethy 
lamine. Thus obtained bischloroformate Was dissolved in 
dry acetonitrile and conjugated With bishydroXymethyl-5 
?uorouracil. The column chromatography on silicagel 
afforded 95 mg of codrug (79% yield) as a White solid foam. 
1H-NMR (CDCl3) 6 0.64 (s, 3H, C-18), 0.92 (s, 3H, C-19), 
3.73 (m, 8H, PEG), 4.22—4.38 (m, 8H, PEG), 4.59 (m, 1H, 
C-3), 5.20 (dd, 2H, C-21), 5.70 (m, 4H, 2><OCH2N), 7.68, 
7.70 (2d, 2><CH=CF), 9.72, 9.83 (2d, 2H, NH) ppm; 
13C-NMR (CDCl3) 6 205.0 (C-20), 157.2, 156.9 (2d, 2><C 
4‘), 154.9, 154.7, 154.6, 154.5 (4><OCOO), 149.3, 149.2 
(2><C-2‘), 140.2 (d, C-F), 128.4 (d, C-6‘), 90.4 (C-17), 78.3 
(C-3), 23.1 (C-19), 14.7 (C-18) ppm. See synthesis sheme 17 
beloW. 
EXAMPLE 23 
Codrugs from THS, 5FU and Tetraethylene Glycol 
3ot,17ot-21-trihydroXy-5[3 pregnane-20-one (THS) can be 
formulated in to a codrug With 5FU and tetraethylene glycol 
to form an angiostatic steroid. 112.9 mg of the prodrug 
prepared from THS and tetraethylene glycol Was dissolved 
in 3 mL of dry THF and triethylamine (55 pL) Was added 
folloWed by the solution of phosgene (2.81 mL). The miX 
ture Was stirred at room temperature overnight, evaporated 
to dryness, redissolved in dry acetonitrile (2 mL) and added 
to the stirred solution of bishydroXymethyl-5-?uorouracil 
(150 mg) and triethylamine (66.3 pL) in acetonitrile (5 mL). 
After 14 hours at room temperature the products Were 
isolated and puri?ed by column chromatography affording 
the tWo codrugs: more polar 15 (129.3 mg, 69% yield) and 
less polar 16 (20.7 mg, 14% yield), both as White solid 
foams. 15 1H-NMR (CDCl3) 6 0.62 (s, 3H, C-18), 0.95 (s, 
3H, C-19), 3.64—3.78 (m, 12H, PEG), 4.29—4.37 (m, 4H, 
2><OCOOCH2), 4.63 (m, 1H, C-3), 5.00(dd, 2H, C-21), 5.65, 
5.67 (2s, 4H, 2><NCH O), 7.65 (2d, 2H, CH=CF), 9.25, 
9.35 (2><NH) ppm; 1 C-NMR (CDCl3) 6 205.0 (C-20), 
154.9, 154.6, 154.1 (3><OCOO), 90.1 (C-17), 80.0 (C-3), 
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23.1 (019), 14.6 (C-18) ppm. 16 1H-NMR(CDC13) 6 0.66 
(s, 3H, C-18), 0.94 (s, 3H, c-19), 3.61—3.79 (m, 14H, 
OCHZ-PEG), 4.30—4.34 (m, 2H, ocoocnz), 4.64 (m, 1H, 
03), 4.98 (dd, 2H, c-21), 5.65 (s, 2H, OCHZN), 7.62 (01, 
C6‘), E.70 (1H, NH) ppm; 13c-NMR (CDC13) 6 204.5 
(020), 156.2 (d, c-4‘), 154.9, 154.2 (2><ocoo), 148.7 
(c-2‘), 140.1 (d, C-F), 128.1 (d, C-6‘), 90.2 (017), 80.0 
(03), 72.3 (OCOOQH2) 71.4 (OCHZN), 67.6 (CHZOH), 
23.1 (C-19), 14.7 (C-18) ppm. See synthesis sheme 18 
beloW. 
EXAMPLE 24 
Codrug from PG-Fza Triacetate and Timolol 
Prostaglandin E2 alpha (PGF2ot) can be formulated into a 
codrug With timolol (TM) as set forth beloW. PG-Fza triac 
etate (95.4 mg) Was dissolved in 3 mL of dry dichlo 
romethane and DCC (41.2 mg) Was added folloWed by 
dimethylaminopyridine (10 mg). The mixture Was stirred at 
room temperature for 15 min. and the solution of timolol 
(119.6 mg) in 1 mL of dichloromethane Was added. 
The resulting mixture Was stirred at room temperature 
overnight, ?ltered, diluted With dichloromethane, Washed 
With Water, brine and ?nally dried over sodium sulfate. The 
residue after solvent evaporation Was separated by column 
chromatography affording the codrug (61.3 mg, 39.7% 
yield) as an oil. 1H-NMR (CDCl3), 6 0.88 (t, 3H), 1.07 (s, 
9H), 1.24—1.7 (m, 14H), 2.02 (s, 3H), 2.04 (s, 3H), 2.05 (s, 
3H), 2.30 (m, 2H), 2.54 (m, 2H), 2.80 (d, 2H), 3.50 (m, 4H), 
3.78 (t, 4H), 4.58 (m, 2H), 4.88 (m, 1H), 5.08 (t, 1H), 5.23 
(m, 2H), 5.34 (m, 2H), 5.53 (m, 2H) ppm. See synthesis 
sheme 19 beloW. 
Dosages may be calculated by those of skill in the art in 
accordance With methods set forth in Goodman and Gilman, 
The Pharmacological Basis of Therapeutics, 8th Ed., Per 
gamon Press, NY, 1990; and The Merck Index, 11th Ed., 
Merck and Co., Inc., Rahway, NJ. 1989; incorporated herein 
by reference in their entireties. Dosages are preferably in the 
range of about 1 to about 500 mg/kg body Weight, and are 
administered preferably 1 to 2 times a day. 
SCHEME 1 















